Skip to Content
U.S. National Institutes of Health
Cancer Diagnosis Program Cancer Imaging Program Cancer Therapy Evaluation Program Developmental Therapeutics Program Radiation Research Program Translational Research Program Biometric Research Branch Office of Cancer Complementary and Alternative Medicine
Last Updated: 04/25/2012

Spotlight On…

Selected Major Accomplishments of CTEP: 2005 - 2011

  • Over 30 Practice-Changing Clinical Trials including therapeutic agents and other modalities, with 4 announced in first 6 months of 2011

    • ACOSOG-Z0011 — Surgery: SLND not inferior to Axillary Dissection in SLN+ BC
    • NCIC-CTG MA.20 — RT: Regional Nodal RT reduces LR & improves DFS in Node+ BC
    • COG-AALL0232 — Pediatrics: High Dose MTX improves EFS in pediatric ALL
    • RTOG-94-08 — Multimodality: Short-term ADT with RT improves OS in prostate cancer

  • Over 10 FDA Indications — New Oncology Agents (Yr FDA Approval)

    • Bevacizumab — CRC (2006); NSCLC (2006); Renal Cell Cancer (2009)
    • Imatinib mesylate — Pediatric CML (2006); Adjuvant GIST (2008)
    • Nelarabine — T-ALL and T-LBL (2005)
    • Rituximab — Diffuse Large B-cell Lymphoma (2006); Follicular NHL (2006)
    • Trastuzumab — Adjuvant Therapy for Early-stage Her2+ Breast Cancer (2006)
    • Thalidomide — Newly Diagnosed Multiple Myeloma (2006)
    • Anti-GD2 Antibody (ch14.18) in Neuroblastoma (BLA Currently in Preparation)

  • Examples: New Indications Generic Agents (Yr Publication/Press Release)

    • Daunorubicin in AML (2009); Dexamethasone in Multiple Myeloma (2007)